Medicine & Health17 November 2025
Less is More: Reducing Dose Improves Cancer Therapy Completion
Source PublicationClinical Nuclear Medicine
Primary AuthorsWang, Patterson, Akhavanallaf et al.
A targeted radiotherapy called 177Lu-DOTATATE is an effective weapon against neuroendocrine tumours (NETs), but completing the standard four cycles can be challenging for some patients. A new retrospective analysis from the University of Michigan examined how adjusting the treatment plan for 173 patients affected their ability to finish the course.
Researchers found a clear winner in their approach. For patients struggling with side effects, reducing the radiation dose by half proved highly successful, leading to a greater number of them completing all four therapy cycles. In contrast, simply delaying the time between cycles was found to lead to worsened outcomes.
The study reinforces that the therapy is generally well-tolerated, with side effects like temporary drops in blood cell counts that later rebounded. This research highlights the importance of personalising treatment, showing that for this therapy, a lower dose can be a more effective strategy than a longer break.
Researchers found a clear winner in their approach. For patients struggling with side effects, reducing the radiation dose by half proved highly successful, leading to a greater number of them completing all four therapy cycles. In contrast, simply delaying the time between cycles was found to lead to worsened outcomes.
The study reinforces that the therapy is generally well-tolerated, with side effects like temporary drops in blood cell counts that later rebounded. This research highlights the importance of personalising treatment, showing that for this therapy, a lower dose can be a more effective strategy than a longer break.
Cite this Article (Harvard Style)
Wang et al. (2025). 'Less is More: Reducing Dose Improves Cancer Therapy Completion'. Clinical Nuclear Medicine. Available at: https://doi.org/10.1097/rlu.0000000000006162